Author:
Chinsangaram Jarasvech,Honeychurch Kady M.,Tyavanagimatt Shanthakumar R.,Leeds Janet M.,Bolken Tove' C.,Jones Kevin F.,Jordan Robert,Marbury Thomas,Ruckle Jon,Mee-Lee Denis,Ross Eric,Lichtenstein Israel,Pickens Margaret,Corrado Michael,Clarke Jean M.,Frimm Annie M.,Hruby Dennis E.
Abstract
ABSTRACTST-246 is being evaluated as a treatment for pathogenic orthopoxvirus infections in humans. To this end, a phase 2, double-blind, randomized, placebo-controlled, multicenter trial was conducted to assess the safety, tolerability, and pharmacokinetics (PK) of ST-246 when administered as a single daily oral dose (400 mg or 600 mg) for 14 days in fed adult volunteers. ST-246 was safe and well tolerated, with no deaths or serious adverse events reported during the study. There was a low incidence of treatment-emergent adverse events (TEAEs), the most common of which were mild nausea and headache. There were no clinically significant results from laboratory assessments, vital sign measurements, physical examinations, or electrocardiograms. The PK and dose proportionality of ST-246 were determined. The PK analysis showed that steady state was achieved by day 5 for the ST-246 400-mg treatment group and by day 6 for the 600-mg group. The dose proportionality analysis showed that the 400- and 600-mg ratio of dose-normalized peak drug concentration in plasma (Cmax) and relative exposure for each dosing interval (AUCτ) ranged from 80% to 85%. However, the 90% confidence intervals did not include 1.0, so dose proportionality could not be concluded. Overall, ST-246 was shown to be safe, and the PK was predictable. These results support further testing of ST-246 in a multicenter pivotal clinical safety study for licensure application.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference16 articles.
1. N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2-(1H)-yl) carboxamides: identification of novel orthopoxvirus egress inhibitors;Bailey;J. Med. Chem.,2007
2. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections;Baker;Antiviral Res.,2003
3. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination;Bray;Antiviral Res.,2003
4. Antiviral prophylaxis of smallpox;Bray;J. Antimicrob. Chemother.,2004
5. Poxviruses;Buller,1999
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献